Insights Into Hodgkin Lymphoma (HL)

Perspectives of community physicians from across the US on the management of Hodgkin lymphoma (HL) with regard to clinical and nonclinical factors impacting treatment selection

California – February 18, 2023

Faculty Chair

Joseph Tuscano, MD

University of California Davis Health, Sacramento, CA, USA

Northeast – February 25, 2023

Faculty Chair

Joanna Rhodes, MD

Northwell Health, New York, NY, USA

Mid-Atlantic – February 25, 2023

Faculty Chair

Barbara Pro, MD

Columbia University Irving Medical Center, New York, NY, USA

Southeast – March 11, 2023

Faculty Chair

Vincent Herrin, MD

Merit Health Central, Jackson, MS, USA

Midwest #1 – March 11, 2023

Faculty Chair

Narendranath Epperla, MD

The Ohio State University Wexner Medical Center, Columbus, OH, USA

Northwest – March 18, 2023

Faculty Chair

Krish Patel, MD

Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA

Central #1 – March 18, 2023

Faculty Chair

Radhakrishnan Ramchandren, MD

The University of Tennessee, Knoxville, TN, USA

Southwest – March 25, 2023

Faculty Chair

Jeffrey Schriber, MD, FRCP

Cancer Treatment Centers of America, Phoenix, AZ, USA

Midwest #2 – April 1, 2023

Faculty Chair

John Burke, MD

Rocky Mountain Cancer Centers, Aurora, CO, USA

Central #2 – April 22, 2023

Faculty Chair

Andrew Whiteley, MD

Texas Oncology, Dallas, TX, USA

More Information

  • Sacramento, CA
  • California

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Philadelphia, PA
  • Mid-Atlantic Region

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Columbus, OH
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

More Information

  • Nashville, TN
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Las Vegas, NV
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Denver, CO
  • Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Dallas, TX
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report


  • Assess advisors’ current management of cHL
  • Gain insights into advisors’ perceptions of available therapies and understanding of data
  • Understand the impact of pathways and other nonclinical factors that may affect treatment selection


  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.